Peridex

Chlorhexidine Gluconate


Xttrium Laboratories, Inc.
Human Prescription Drug
NDC 0116-0620
Peridex also known as Chlorhexidine Gluconate is a human prescription drug labeled by 'Xttrium Laboratories, Inc.'. National Drug Code (NDC) number for Peridex is 0116-0620. This drug is available in dosage form of Rinse. The names of the active, medicinal ingredients in Peridex drug includes Chlorhexidine Gluconate - 1.2 mg/mL . The currest status of Peridex drug is Active.

Drug Information:

Drug NDC: 0116-0620
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Peridex
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Chlorhexidine Gluconate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Xttrium Laboratories, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Rinse
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CHLORHEXIDINE GLUCONATE - 1.2 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 13 Aug, 1986
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 18 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019028
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Xttrium Laboratories, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:834127
834135
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:MOR84MUD8E
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Decreased Cell Wall Integrity [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0116-0620-01473 mL in 1 BOTTLE (0116-0620-01)13 Aug, 1986N/ANo
0116-0620-021893 mL in 1 BOTTLE, DISPENSING (0116-0620-02)16 Jan, 2013N/ANo
0116-0620-03118 mL in 1 BOTTLE (0116-0620-03)16 Jan, 2013N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Peridex chlorhexidine gluconate glycerin saccharin sodium fd&c blue no. 1 water alcohol chlorhexidine gluconate chlorhexidine mint

Indications and Usage:

Indications and usage peridex is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. peridex has not been tested among patients with acute necrotizing ulcerative gingivitis (anug). for patients having coexisting gingivitis and periodontitis, see precautions .

Warnings:

Warnings the effect of peridex on periodontitis has not been determined. an increase in supragingival calculus was noted in clinical testing in peridex users compared with control users. it is not known if peridex use results in an increase in subgingival calculus. calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. see contraindications .

General Precautions:

General for patients having coexisting gingivitis and periodontitis, the presence or absence of gingival inflammation following treatment with peridex should not be used as a major indicator of underlying periodontitis. peridex can cause staining of oral surfaces, such as tooth surfaces, restorations, and the dorsum of the tongue. not all patients will experience a visually significant increase in toothstaining. in clinical testing, 56% of peridex users exhibited a measurable increase in facial anterior stain, compared to 35% of control users after six months; 15% of peridex users developed what was judged to be heavy stain, compared to 1% of control users after six months. stain will be more pronounced in patients who have heavier accumulations of unremoved plaque. stain resulting from use of peridex does not adversely affect health of the gingivae or other oral tissues. stain can be removed from most tooth surfaces by conventional professional prophylactic techniques. additional time
may be required to complete the prophylaxis. discretion should be used when prescribing to patients with anterior facial restorations with rough surfaces or margins. if natural stain cannot be removed from these surfaces by a dental prophylaxis, patients should be excluded from peridex treatment if permanent discoloration is unacceptable. stain in these areas may be difficult to remove by dental prophylaxis and on rare occasions may necessitate replacement of these restorations. some patients may experience an alteration in taste perception while undergoing treatment with peridex. rare instances of permanent taste alteration following peridex use have been reported via post-marketing product surveillance.

Dosage and Administration:

Dosage and administration peridex therapy should be initiated directly following a dental prophylaxis. patients using peridex should be reevaluated and given a thorough prophylaxis at intervals no longer than six months. recommended use is twice daily oral rinsing for 30 seconds, morning and evening after toothbrushing. usual dosage is 15ml (marked in cap) of undiluted peridex. patients should be instructed to not rinse with water or other mouthwashes, brush teeth or eat immediately after using peridex. peridex is not intended for ingestion and should be expectorated after rinsing.

Contraindications:

Contraindications peridex should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

Adverse Reactions:

Adverse reactions the most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception, see warnings and precautions . oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse. the following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. each occurred at a frequency of less than 1.0%. among post marketing reports, the most frequently reported oral mucosal symptoms associated with peridex are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia. minor irritation and superficial desquamation of
the oral mucosa have been noted in patients using peridex. there have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using peridex.

Use in Pregnancy:

Pregnancy teratogenic effects pregnancy reproduction studies have been performed in rats and rabbits at chlorhexidine gluconate doses up to 300mg/kg/day and 40mg/kg/day, respectively, and have not revealed evidence of harm to fetus. however, adequate and well-controlled studies in pregnant women have not been done. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pediatric Use:

Pediatric use clinical effectiveness and safety of peridex have not been established in children under the age of 18.

Overdosage:

Overdosage ingestion of 1 or 2 ounces of peridex by a small child (~10 kg body weight) might result in gastric distress, including nausea, or signs of alcohol intoxication. medical attention should be sought if more than 4 ounces of peridex is ingested by a small child or if signs of alcohol intoxication develop.

Description:

Description peridex™ (chlorhexidine gluconate 0.12%) oral rinse is an oral rinse containing 0.12% chlorhexidine gluconate (1, 1 1 -hexamethylene bis [5-(p-chlorophenyl) biguanide] di-d-gluconate) in a base containing water, 11.6% alcohol, glycerin, peg-40 sorbitan diisostearate, flavor, sodium saccharin, and fd&c blue no. 1. peridex is a near-neutral solution (ph range 5-7). chlorhexidine gluconate is a salt of chlorhexidine and gluconic acid. its chemical structure is: chem

Clinical Pharmacology:

Clinical pharmacology peridex (chlorhexidine guconate 0.12%) oral rinse provides antimircobial activity during oral rinsing. the clinical significance of peridex oral rinse's antimicrobial activities is not clear. microbiological sampling of plaque has shown a general reduction of counts of certain assayed bacteria, both aerobic and anaerobic, ranging from 54-97% through six months use. use of peridex in a six month clinical study did not result in any significant changes in bacteria resistance, overgrowth of potentially opportunistic organisms or other adverse changes in the oral microbial ecosystem. three months after peridex use was discontinued, the number of bacteria in plaque had returned to baseline levels and resistance of plaque bacteria to chlorhexidine gluconate was equal to that at baseline. pharmacokinetics pharmacokinetic studies with peridex indicate approximately 30% of the active ingredient, chlorhexidine gluconate, is retained in the oral cavity following rinsing. thi
s retained drug is slowly released into the oral fluids. studies conducted on human subjects and animals demonstrate chlorhexidine gluconate is poorly absorbed from the gastrointestinal tract. the mean plasma level of chlorhexidine gluconate reached a peak of 0.206 mcg/g in humans 30 minutes after they ingested a 300-mg dose of the drug. detectable levels of chlorhexidine gluconate were not present in the plasma of these subjects 12 hours after the compound was administered. excretion of chlorhexidine gluconate occurred primarily through the feces (~90%). less than 1% of the chlorhexidine gluconate ingested by these subjects was excreted in the urine.

Pharmacokinetics:

Pharmacokinetics pharmacokinetic studies with peridex indicate approximately 30% of the active ingredient, chlorhexidine gluconate, is retained in the oral cavity following rinsing. this retained drug is slowly released into the oral fluids. studies conducted on human subjects and animals demonstrate chlorhexidine gluconate is poorly absorbed from the gastrointestinal tract. the mean plasma level of chlorhexidine gluconate reached a peak of 0.206 mcg/g in humans 30 minutes after they ingested a 300-mg dose of the drug. detectable levels of chlorhexidine gluconate were not present in the plasma of these subjects 12 hours after the compound was administered. excretion of chlorhexidine gluconate occurred primarily through the feces (~90%). less than 1% of the chlorhexidine gluconate ingested by these subjects was excreted in the urine.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility in a drinking water study in rats, carcinogenic effects were not observed at doses up to 38mg/kg/day. mutagenic effects were not observed in two mammalian in vivo mutagenesis studies with chlorhexidine gluconate. the highest doses of chlorhexidine used in a mouse dominant-lethal assay and a hamster cytogenetics test were 1000mg/kg/day and 250mg/kg/day, respectively. no evidence of impaired fertility was observed in rats at doses up to 100mg/kg/day.

How Supplied:

How supplied peridex is supplied as a blue liquid in 4-ounce (118ml), 1-pint (473ml) and 64-ounce (1893ml) white or amber plastic bottles with child-resistant dispensing closures. store at 20°c to 25°c (68°f to 77°f ), excursions permitted to 15°c to 30°c (59°f to 86°f) [see usp controlled room temperature]. rx only keep out of reach of children

Spl Patient Package Insert:

What to expect when using peridex (chlorhexidine gluconate 0.12%) oral rinse your dentist has prescribed peridex™ (chlorhexidine gluconate 0.12%) oral rinse to treat your gingivitis, to help reduce the redness and swelling of your gums, and also to help you control any gum bleeding. use peridex regularly, as directed by your dentist, in addition to daily brushing. spit out after use. peridex should not be swallowed. if you develop allergic symptoms such as skin rash, itch, generalized swelling, breathing difficulties, light headedness, rapid heart rate, upset stomach or diarrhea, seek medical attention immediately. peridex should not be used by persons who have a sensitivity to it or its components. peridex may cause some tooth discoloration or increase in tartar (calculus) formation, particularly in areas where stain and tartar usually form. it is important to see your dentist for removal of any stain or tartar at least every six months or more frequently if your dentist advises.
both stain and tartar can be removed by your dentist or hygienist. peridex may cause permanent discoloration of some front-tooth fillings. to minimize discoloration, you should brush and floss daily, emphasizing areas which begin to discolor. peridex may taste bitter to some patients and can affect how foods and beverages taste. this will become less noticeable in most cases with continued use of peridex. to avoid taste interference, rinse with peridex after meals. do not rinse with water or other mouthwashes immediately after rinsing with peridex. if you have any questions or comments about peridex, contact your dentist, pharmacist or 3m espe dental products toll free at 1-800-634-2249. call your healthcare provider for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. store at 20°c to 25°c (68°f to 77°f ), excursions permitted to 15°c to 30°c (59°f to 86°f) [see usp controlled room temperature]. revised: july 2022 made in u.s.a. for: 3m espe dental products 2510 conway avenue st. paul, mn 55144-1000 u.s.a. © 3m 2022

Package Label Principal Display Panel:

Ndc 48878-0620-4 peridex (chlorhexidine gluconate 0.12%) oral rinse directions for use: swish in mouth undiluted for 30 seconds, then spit out. use after breakfast and before bedtime, or use as prescribed. note: to minimize medicinal taste, do not rinse with water immediately after use. to open, press down while turning cap. to reseal, turn cap past "clicks" until tightly locked. rx only keep out of reach of children ndc 48878-0620-3 peridex (chlorhexidine gluconate 0.12%) oral rinse, usp directions for use: swish 1 tablespoon (15 ml) in mouth undiluted for 30 seconds, then spit out. use after breakfast and before bedtime. or, use as prescribed. note: to minimize medicinal taste, do not rinse with water immediately after use. rx only keep out of reach of children ingredients: 0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, peg-40 sorbitan diisostearate, flavor, sodium saccharin and fd&c blue no. 1. to open, press down while turning cap. to reseal, turn cap past "clicks" until tightly locked. 4 oz. (118 ml) ref 12134 peridex04bldla ndc 48878-0620-1 peridex (chlorhexidine gluconate 0.12%) oral rinse directions for use: fill cap to the "fill line" (15 ml). swish in mouth undiluted for 30 seconds, then spit out. use after breakfast and before bedtime, or, use as prescribed note: to minimize medicinal taste, do not rinse with water immediately after use. rx only keep out of reach of children dispense in bottle as provided or in amber glass ref 12132 3m espe i.d. no. 70-2010-5520-1 1 pint (473 ml) peridex16lbldlb ndc 48878-0620-2 peridex (chlorhexidine gluconate 0.12%) oral rinse directions for use: remove bottle cap and replace with dispensing pump. turn pump counterclockwise to release pump spring mechanism and seal. dispense two complete pumps of the oral rinse, an appropriate deliverable volume of 15 ml, into a suitable patient cup. swish in mouth undiluted for 30 seconds, then spit out. note: to minimize medicinal taste, do not rinse with water immediately after use. ingredients: 0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, peg-40 sorbitan diisostearate, flavor, sodium saccharin and fd&c blue no. 1. rx only keep out of reach of children 64 fl oz (1893 ml) ref 12133 3m espe i.d. no. 70-2010-5521-0 3m espe 64peribtllbldla pdp pi2 pi3 pi4 pdp16 pi216 pi316 pil pdp64 pi264 pi364 pib


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.